Parallel Advisors LLC Buys 158 Shares of Becton, Dickinson and Company (NYSE:BDX)

Parallel Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,569 shares of the medical instruments supplier’s stock after acquiring an additional 158 shares during the period. Parallel Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Livelsberger Financial Advisory purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $29,000. Scarborough Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at $32,000. Rise Advisors LLC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at $38,000. Finally, ICA Group Wealth Management LLC acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at $42,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.6 %

BDX opened at $234.18 on Monday. The business’s fifty day simple moving average is $234.71 and its 200 day simple moving average is $235.61. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $269.52. The firm has a market cap of $67.68 billion, a P/E ratio of 51.58, a PEG ratio of 1.91 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.96 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Citigroup lowered their target price on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI cut their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.